Neurocrine Biosciences Publishes Key Review on Tardive Dyskinesia Treatment with INGREZZA®

Neurocrine Biosciences Enhances Understanding of Tardive Dyskinesia Treatment with New Review Publication

Neurocrine Biosciences, Inc. has made a significant contribution to the treatment landscape of tardive dyskinesia with the recent publication of a peer-reviewed narrative review in the journal CNS Spectrums. This review focuses on the pharmacologic and clinical data surrounding VMAT2 inhibitors, specifically highlighting INGREZZA® (valbenazine) capsules and deutetrabenazine. The comprehensive analysis, authored by experts in psychiatry and neurology, emphasizes the distinct characteristics and clinical implications of these two FDA-approved treatments. By providing a thorough examination of clinical study results, safety profiles, and dosing considerations, the review serves as a critical resource for healthcare providers seeking to optimize therapeutic decisions for patients suffering from tardive dyskinesia.

One of the key highlights of the review is the unique mechanism of action of INGREZZA, which selectively targets the VMAT2 receptor. Unlike deutetrabenazine, which has different dosing requirements and may involve titration, INGREZZA offers a simplified treatment regimen with effective therapeutic responses at a low starting dose of 40 mg. This no-titration dosing approach not only eases the treatment process for patients but also enhances adherence, an essential factor in managing chronic conditions like tardive dyskinesia. The review underscores that VMAT2 inhibitors should not be viewed as interchangeable, advocating for personalized treatment plans that consider each medication's specific pharmacologic attributes and clinical data.

Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences, underscores the publication's importance in guiding healthcare providers toward informed treatment choices. By emphasizing the extensive clinical data supporting INGREZZA, the review not only promotes a nuanced understanding of VMAT2 inhibitors but also positions Neurocrine Biosciences as a leader in advancing therapeutic options for tardive dyskinesia. The research findings bolster the argument for tailored treatment approaches, helping clinicians navigate the complexities of managing this challenging condition.

In a broader context, the publication reflects Neurocrine's commitment to improving patient outcomes through evidence-based resources. As healthcare providers increasingly seek to understand the nuanced differences between available treatments, this review serves as a vital tool in ensuring that patients receive the most appropriate and effective care for tardive dyskinesia. Furthermore, the emphasis on distinct pharmacologic mechanisms reinforces the importance of ongoing research and education in the neurology and psychiatry fields.